Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Aeterna Zentaris Inc.
QUÉBEC CITY, Feb. 3, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that presentations on two of its oncology compounds, zoptarelin doxorubicin (AEZS-108) and disorazol Z, will be made during the 11th International Symposium on GnRH, in Salzburg, Austria, February 9 -11, 2014.
The session will be held on Tuesday, February 11, 2014, in Hall A of the
Wyndham Hotel in Salzburg.
Presentations are scheduled as follows:
|10:30 am||"Zoptarelin Doxorubicin (AEZS-108) New Drug Targeting Concept: Overview of Clinical Results"|
|Speaker: Dr. Günter Emons, Chairman, Department of Obstetrics & Gynaecology, Georg-August University Göttingen, Germany|
|11:00 am||"Zoptarelin Doxorubicin (AEZS-108) New Drug Targeting Concept: GnRH Receptor Targeting in Triple-Negative Breast Cancer"|
|Speaker: Dr. Jörg B. Engel, Medical University of Regensburg, Department of Gynaecology and Obstetrics, Germany|
|11:15 am||"New and Highly Potent Disorazol Z GnRH Conjugates: Concept and Mode of Action"|
|Speaker: Dr. Babette Aicher, Director, Preclinical Development, Aeterna Zentaris|
|11:45 am||"New and Highly Potent Disorazol Z GnRH Conjugates: Preclinical Results in Endometrial Cancers"|
|Speaker: Dr. Carsten Gruendker, Department of Obstetrics & Gynaecology, Georg-August University Göttingen, Germany|
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The Company's pipeline encompasses compounds from drug discovery to regulatory approval. For more information, visit www.aezsinc.com.
This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the ability of the Company to efficiently commercialize one or more of its products or product candidates, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.
©2012 PR Newswire. All Rights Reserved.